Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02729714 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
A Phase 4 study of Insomnia, sponsored by Burdick, Daniel, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02729714: Completed Phase 4 study of Insomnia, sponsored by Burdick, Daniel, M.D..
NCT02729714 is a Phase 4 study of Insomnia that has completed, run by Burdick, Daniel, M.D.. The registered enrollment target is 21 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02729714, a Phase 4 study of Insomnia, has completed, sponsored by Burdick, Daniel, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the study drug, suvorexant, is safe and effective in treating symptoms of insomnia in people with Parkinson's Disease. It is anticipated that a total of 20 subjects, 30 to 80 years of age, with Parkinson's Disease and symptoms of insomnia will participate in the study at this site
Primary Outcome
Sleep efficiency is defined as total sleep time divided by total time in bed, expressed as a percent. Polysomnograms were performed at baseline, end of treatment period 1, and end of treatment period 2. A positive change indicates improvement in sleep efficiency. Assessing difference between change in sleep efficiency during suvorexant period and change in sleep efficiency during placebo period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Suvorexant
Study Locations (1)
Washington
- Evergreenhealth Booth Gardner Parkinsons Care Center - Kirkland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-04 |
| Est. Completion | 2022-04 |
| Phase | Phase 4 |
What the finished NCT02729714 record still lists
NCT02729714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02729714 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT02729714 about?
NCT02729714 is a clinical study titled "A Pilot Study of Suvorexant for Insomnia in Parkinson Disease". The purpose of this study is to see if the study drug, suvorexant, is safe and effective in treating symptoms of insomnia in people with Parkinson's Disease. It is anticipated that a total of 20 subjects, 30 to 80 years of age, with Parkinson's Disease and symptoms of insomnia will participate in th...
What is the current status of trial NCT02729714?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2016-04. Estimated completion is 2022-04.
What conditions does trial NCT02729714 study?
This clinical trial studies the following conditions: Insomnia.
What interventions are being tested in trial NCT02729714?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT02729714?
This trial is sponsored by Burdick, Daniel, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02729714 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02729714's enrollment target sits among peer trials
21 136th of 151 higher than 16 of 151 other Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
RECRUITING · Phase 4
-
Enhancing Hypnotic Medication Discontinuation in Primary Care
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial
ACTIVE NOT RECRUITING · Phase 4
-
Solriamfetol and CBT-I in Patients With Insomnia Disorder
ACTIVE NOT RECRUITING · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia